Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome

Anavex Life Sciences Announces ANAVEX®2-73 Biomarker Correlated with Efficacy Endpoint in Trial

Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)

Anavex Life Sciences Announces Participation at Worldwide NIH Panel at Rare Disease Day®